This study is currently not recruiting participants.
A randomized double-blind placebo-controlled parallel-group multi-center event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care (FIGARO-DKD)
Not Recruiting
100 years or below
All
Phase
N/A
1 Location
Brief description of study.
The purpose of this study is to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular (CV) mortality and morbidity in subjects with type 2 diabetes mellitus (T2DM) and the clinical diagnosis of diabetic kidney disease (DKD).
Detailed description of study
The purpose of this study is to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular (CV) mortality and morbidity in subjects with type 2 diabetes mellitus (T2DM) and the clinical diagnosis of diabetic kidney disease (DKD).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
